SIMTRIYO (CENTANAFADINE): FIRST-IN-CLASS ADHD MEDICATION AVAILABLE SOON
Simtriyo is the first triple reuptake inhibitor approved for ADHD
Straight Healthcare
November 2026
November 2026
Simtriyo (centanafadine), an extended-release capsule, is the first norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) approved for ADHD. It recently received a DEA schedule, and the manufacturer is expected to release it later this year. Traditional ADHD stimulants like methylphenidate and amphetamines act on dopamine and norepinephrine. Centanafadine acts on these plus serotonin. Methylphenidate and amphetamines are DEA Schedule II medications, while Simtriyo received a DEA Schedule III designation.
Centanafadine's efficacy was evaluated in four 6-week, randomized, double-blind, placebo-controlled trials. In children aged 6 to 12 years (N=480), it lowered ADHD-RS-5 total scores (scale 0 - 54; lower better) by 16.3 points, compared with 10.8 points for placebo (difference, −5.6; 95% CI, −8.78 to −2.33). In adolescents (N=459), it lowered scores by 18.5 versus 14.2 points, respectively (difference, −4.4; 95% CI, −6.83 to −1.87). In two adult trials (N=906), AISRS total scores (scale 0 - 54; lower better) improved 2.7 to 4.4 points more than with placebo. Simtriyo has not been compared head-to-head with other stimulants.
Adult dosing starts at 210 mg once daily, with titration to a maximum of 280 mg. Adolescent dosing is 280 mg once daily, and children aged 6 to 12 years old are dosed by weight: 140 mg for 20 to <35 kg, 210 mg for 35 to 50 kg, and 280 mg for >50 kg. Capsules can be swallowed whole or opened and sprinkled on applesauce, yogurt, or orange juice. Centanafadine is a moderate CYP1A2 inhibitor, and providers should monitor for adverse effects and consider lowering the dose of CYP1A2 substrates (e.g., theophylline, tizanidine, clozapine, duloxetine). Precautions and side effects are similar to those of other stimulants and include decreased appetite, insomnia, blood pressure and heart rate increases, growth suppression in children, and a boxed warning for abuse, misuse, and addiction. A second boxed warning addresses suicidal ideation and behavior, which occurred more often in children aged 6 to 12 years.
Centanafadine's efficacy was evaluated in four 6-week, randomized, double-blind, placebo-controlled trials. In children aged 6 to 12 years (N=480), it lowered ADHD-RS-5 total scores (scale 0 - 54; lower better) by 16.3 points, compared with 10.8 points for placebo (difference, −5.6; 95% CI, −8.78 to −2.33). In adolescents (N=459), it lowered scores by 18.5 versus 14.2 points, respectively (difference, −4.4; 95% CI, −6.83 to −1.87). In two adult trials (N=906), AISRS total scores (scale 0 - 54; lower better) improved 2.7 to 4.4 points more than with placebo. Simtriyo has not been compared head-to-head with other stimulants.
Adult dosing starts at 210 mg once daily, with titration to a maximum of 280 mg. Adolescent dosing is 280 mg once daily, and children aged 6 to 12 years old are dosed by weight: 140 mg for 20 to <35 kg, 210 mg for 35 to 50 kg, and 280 mg for >50 kg. Capsules can be swallowed whole or opened and sprinkled on applesauce, yogurt, or orange juice. Centanafadine is a moderate CYP1A2 inhibitor, and providers should monitor for adverse effects and consider lowering the dose of CYP1A2 substrates (e.g., theophylline, tizanidine, clozapine, duloxetine). Precautions and side effects are similar to those of other stimulants and include decreased appetite, insomnia, blood pressure and heart rate increases, growth suppression in children, and a boxed warning for abuse, misuse, and addiction. A second boxed warning addresses suicidal ideation and behavior, which occurred more often in children aged 6 to 12 years.
- Simtriyo (centanafadine) review
- Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With ADHD, J Clin Psychopharmacol (2022) [PubMed abstract]
- Centanafadine for ADHD in Adolescents: A Randomized Clinical Trial, J Am Acad Child Adolesc Psychiatry (2026) [PubMed abstract]
